Dr Navaneethan Palanisamy

Biography

Navaneethan completed his BTech in Biotechnology at VIT University, Vellore campus (India) in 2010. He did his bachelor thesis under Prof. C. Rajasekaran (VIT University) and Prof. Sunil Nautiyal, ISEC, Bengaluru (India). He then moved to Uppsala University (Sweden) where he completed his MMedSci in Infection Biology in 2013. For his thesis, he worked on tigecycline resistance in Escherichia coli under Prof. Dan I Andersson. In 2012, he received Max Planck Society stipend (Germany) and pursued his MSc in Molecular Biology at Goettingen University (Germany), finishing in 2014. During this period, he did his thesis on Spinach aptamers under Dr. Claudia Hoebartner at Max Planck Institute for Biophysical Chemistry, Goettingen (Germany). After this, he had a short stay at McGill University, Montreal (Canada) working under Prof. Mark Wainberg on drug resistance in human immunodeficiency virus (HIV) and drug development against dengue virus (DENV). Between 2015 and 2020, he did his PhD at Heidelberg University, Heidelberg (Germany) working on chromosome segregation and cell division in E. coli, inteins, and optogenetics in the lab of Prof. Barbara Di Ventura.

Teaching and Supervision

Programme Leader for MSc Infection and Immunity Module Leader for, 1) MD5028 (Advanced Microbiology), 2) MD7006 (Clinical Immunology and Microbial Pathogenesis) & 3) MD7025 (Infectious Disease) Interim Module Leader for, 1) MD7026 (Advanced Immunology) & 2) MD6030 (Medical Microbiology) Delivered Lectures in, 1) MD4008 (Introduction to Microbiology), 2) MD5028 (Advanced Microbiology), 3) MD6028 (Virology), 4) MD6030 (Medical Microbiology), 5) MD6037 (Cell Signalling), 6) MD7006 (Clinical Immunology and Microbial Pathogenesis), 7) MD7025 (Infectious Disease) & 8) MD7026 (Advanced Immunology)

Research and Knowledge Exchange

Main interests: Antimicrobial drug resistance (focus on bacteria and viruses), Bioinformatics (focus on molecular dynamics, sequence analysis & evolutionary studies), Molecular biology (focus on chromosome separation in E. coli & development of molecular biology tools), Biochemistry (focus on protein purification) & Synthetic biology (focus on optogenetics, inteins & aptamers) Publications: Haars J, Palanisamy N, Wallin F, Mölling P, Lindh J, Sundqvist M, Ellström P, Kaden R and Lennerstrand J, 2023. Prevalence of SARS-CoV-2 Omicron Sublineages and Spike Protein Mutations Conferring Resistance against Monoclonal Antibodies in a Swedish Cohort during 2022–2023. Microorganisms 11(10):2417. doi: 10.3390/microorganisms11102417. Smout E, Palanisamy N* and Valappil SP*, 2023. Prevalence of vancomycin-resistant Enterococci in India between 2000 and 2022: a systematic review and meta-analysis. Antimicrob Resist Infect Control 12(1):79. doi: 10.1186/s13756-023-01287-z. *corresponding authors Mannsverk S, Bergholm J, Palanisamy N, Ellström P, Kaden R, Lindh J and Lennerstrand J, 2022. SARS-CoV-2 variants of concern and spike protein mutational dynamics in a Swedish cohort during 2021, studied by Nanopore sequencing. Virol J 19(1):164. doi: 10.1186/s12985-022-01896-x. Lennerstrand J and Palanisamy N*, 2021. Global prevalence of adaptive and prolonged infections’ mutations in the receptor-binding domain of the SARS-CoV-2 spike protein. Viruses 13(10):1974. doi: 10.3390/v13101974. *corresponding author Palanisamy N*, Ballestin Ballestin J and Di Ventura B, 2021. Expanding the SiMPl plasmid toolbox for use with spectinomycin/streptomycin. ACS Omega 6(22):14148–14153. doi:10.1021/acsomega.1c00649. *also the corresponding author Romano E, Baumschlager A, Akmeriç EB, Palanisamy N, Houmani M, Schmidt G, Öztürk MA, Ernst L, Khammash M and Di Ventura B, 2021. Engineering AraC to make it responsive to light instead of arabinose. Nat Chem Biol. doi: 10.1038/s41589-021-00787-6. Akaberi D, Båhlström A, Chinthakindi PK, Nyman T, Sandström A, Järhult JD, Palanisamy N, Lundkvist Å and Lennerstrand J, 2021. Targeting the NS2B-NS3 protease of tick-borne encephalitis virus with pan-flaviviral protease inhibitors. Antiviral Res. doi: 10.1016/j.antiviral.2021.105074. Palanisamy N, Öztürk MA, Akmeriç EB and Di Ventura B, 2020. C-terminal eYFP fusion impairs Escherichia coli MinE function. Open Biol. doi: 10.1098/rsob.200010. Akaberi D, Chinthakindi PK, Båhlström A, Palanisamy N, Sandström A, Lundkvist Å and Lennerstrand J, 2020. Identification of a C2-symmetric diol based human immunodeficiency virus protease inhibitor targeting Zika virus NS2B-NS3 protease. J Biomol Struct Dyn. doi: 10.1080/07391102.2019.1704882. Palanisamy N, Degen A, Morath A, Ballestin Ballestin J, Juraske C, Öztürk MA, Sprenger GA, Youn JW, Schamel WW and Di Ventura B, 2019. Split intein-mediated selection of cells containing two plasmids using a single antibiotic. Nat Commun 10(1):4967. doi:10.1038/s41467-019-12911-1. Kjellin M, Kileng H, Akaberi D, Palanisamy N, Duberg AS, Danielsson A, Kristiansen MG, Nöjd J, Aleman S, Gutteberg T, Goll R, Lannergård A and Lennerstrand J, 2019. Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway. Scand J Gastroenterol 54(8):1042-1050. doi:10.1080/00365521.2019.1652846. Steinmetzger C, Palanisamy N, Gore KR and Höbartner C, 2019. A multicolor large Stokes shift fluorogen-activating RNA aptamer with cationic chromophores. Chemistry-Eur J 25(8):1931-1935. doi:10.1002/chem.201805882. Akaberi D, Bergfors A, Kjellin M, Kameli N, Lidemalm L, Kolli B, Shafer RW, Palanisamy N and Lennerstrand J, 2018. Baseline dasabuvir resistance in Hepatitis C virus from the genotypes 1, 2 and 3 and modeling of the NS5B-dasabuvir complex by the in silico approach. Infect Ecol Epidemiol, 8(1):1528117. doi: 10.1080/20008686.2018.1528117. Palanisamy N*, Kalaghatgi P, Akaberi D, Lundkvist Å, Chen ZW, Hu P and Lennerstrand J, 2018. Worldwide prevalence of baseline resistance-associated polymorphisms and resistance mutations in HCV against current direct-acting antivirals. Antivir Ther, Epub 10 May 2018. doi:10.3851/IMP3237. *also the corresponding author Palanisamy N*, Akaberi D, Lennerstrand J and Lundkvist Å, 2018. Comparative genome analysis of Alkhumra hemorrhagic fever virus with Kyasanur forest disease and tick-borne encephalitis viruses by the in silico approach. Pathog Glob Health, Epub 10 May 2018. doi:10.1080/20477724.2018.1471187. *also the corresponding author Melzer AM and Palanisamy N*, 2018. Deleterious single nucleotide polymorphisms of protein kinase R identified by the computational approach. Mol Immunol, 101:65-73. doi:10.1016/j.molimm.2018.05.026. *corresponding author Palanisamy N*, Akaberi D and Lennerstrand J, 2018. Protein backbone flexibility pattern is evolutionarily conserved in the Flaviviridae family: a case of NS3 protease in Flavivirus and Hepacivirus. Mol Phylogenet Evol, 118:58-63. doi: 10.1016/j.ympev.2017.09.015. *also the corresponding author Palanisamy N* and Lennerstrand J, 2018. Biophysical studies on HCV 1a NS3/4A protease and its catalytic triad in wild type and mutants by the in silico approach. Interdiscip Sci, 10(1):143-156. doi: 10.1007/s12539-016-0177-4. *also the corresponding author Palanisamy N, 2018. Identification of putative drug targets and annotation of unknown proteins in Tropheryma whipplei. Comput Biol Chem,76:130-138. doi: 10.1016/j.compbiolchem.2018.05.024. Xu HT, Colby-Germinario SP, Hassounah SA, Fogarty C, Osman N, Palanisamy N, Han Y, Oliveira M, Quan Y and Wainberg MA, 2017. Evaluation of Sofosbuvir (ß-D-2'-deoxy-2'-a-fluoro-2'-ß-C-methyluridine) as an inhibitor of Dengue virus replication. Sci Rep, 7(1):6345. doi: 10.1038/s41598-01706612-2. Palanisamy N* and Lennerstrand J, 2017. Computational prediction of Usutu virus E protein B-cell and T-cell epitopes for potential vaccine development. Scand J Immunol, 85(5):350-364. doi:10.1111/sji.12544. *also the corresponding author Palanisamy N*, Osman N, Ohnona F, Xu HT, Brenner B, Mesplède T and Wainberg MA, 2017. Does antiretroviral treatment change HIV-1 codon usage patterns in its genes: a preliminary bioinformatics study. AIDS Res Ther, 14:2. doi: 10.1186/s12981-016-0130-y. *also the corresponding author Kokkula C, Palanisamy N*, Ericstam M and Lennerstrand J, 2016. SYBR green II dye-based real-time assay for measuring inhibitor activity against HIV-1 reverse transcriptase. Mol Biotechnol, 58(10):619-625. doi: 10.1007/s12033-016-9961-y. *equal first authors Lindström I, Kjellin M, Palanisamy N, Bondeson K, Wesslén L, Lannergard A and Lennerstrand J, 2015. Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden. Infect Dis (Lond), 47(8): 555-562. doi: 10.3109/23744235.2015.1028097. Eckert N, Wrensch F, Gärtner S, Palanisamy N, Goedecke U, Jäger N, Pöhlmann S and Winkler M, 2014. Influenza A virus encoding secreted Gaussia luciferase as useful tool to analyze viral replication and its inhibition by antiviral compounds and cellular proteins. PLoS One,9(5):e97695. doi: 10.1371/journal.pone.0097695. Danielsson A, Palanisamy N, Golbob S, Yin H, Blomberg J, Hedlund J, Sylvan S and Lennerstrand J, 2014. Transmission of hepatitis C virus among intravenous drug users in the Uppsala region of Sweden. Infect Ecol Epidemiol, 4:22251. doi: 10.3402/iee.v4.22251. Palanisamy N, Danielsson A, Kokkula C, Yin H, Bondeson K, Wesslén L, Duberg AS and Lennerstrand J, 2013. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a. Antiviral Res, 99(1):12-7. doi: 10.1016/j.antiviral.2013.04.018.

Read full biography